been reported in the setting of critically ill patients in general and mostly in patients with sepsis. These facts have been acknowledged and will be included in the product information, as proposed by the PRAC and endorsed by the CMDh by majority vote.
On the contrary, in surgical and trauma patients, the benefit/risk ratio has been evaluated as positive. This is in line with the results of many clinical trials and the recent review article by Van der Linden and colleagues, 5 showing, for example, a decreased requirement of blood transfusion and no difference in mortality and need for renal replacement therapy (RRT). These results confirm that the use of modern HES solutions is safe in the perioperative setting and are congruent with other reports. 6 The judgement of a positive benefit/risk ratio is also in agreement with the majority of stakeholders, who have already expressed their opinion during the EU Article 107i procedure. However, the PRAC has recommended conducting additional clinical studies in the surgical and the trauma setting.
In the letter by Bellomo and associates, it is important to note that many articles are misquoted like the CRISTAL study.
7 In fact, this clinical trial showed that colloids-when given in patients with hypovolaemic shock-are life-saving (significantly reduced 90 day mortality). In this study, 70% of the patients have been treated with HES. In their letter, Bellomo and colleagues did not discuss the major limitations of the three investigator-initiated studies VISEP, 6S, and CHEST. 2 -4 In this context, it is important to note that many patients were already treated before randomization and were not hypovolaemic at the time of study inclusion. Accordingly, there was no need of volume therapy in at least this subset of patients. It is also important to consider that many patients with contra-indications to HES have been included in the studies. In addition, dose limitations have not been respected in the VISEP trial. Overdosing and use outside the indication of hypovolaemia were associated with increased mortality. These criticisms have been expressed by the scientific community. 11 Most importantly, data from the CHEST trial are used incorrectly, although the letter was written and signed by a number of CHEST investigators: 'In CHEST, increased use of renal replacement therapy in intensive care patients occurred after a total cumulative dose of 5 ml/kg, one tenth of the maximal daily dose of 50 ml/kg'. This cannot be correct, since on the first treatment day, a mean dose of 980 ml was administered, which amounts to 12 ml kg 21 . Moreover, the cumulative HES dose within the first 4 days of treatment was 26.5 ml kg 21 . Thus, the cumulative HES dose was greater than five times more than acknowledged by Bellomo and colleagues. It is also important to consider that the difference in the use of RRT was only of borderline significance between groups and that no rules for initiating and stopping RRT were defined. There are also major concerns about study designs and data analyses 11 in VISEP, 6S, and CHEST. Analyses by independent third parties are needed to clarify the open issues. We would also like to express that although some physicians signed the open letter, it is a minority not taking the current status of knowledge of the risk-benefit assessment of HES into account.
In addition, we would like to emphasize that the conduct of further clinical studies is of high value to gain more information on the 'best treatment' of surgical and trauma patients.
Ultimately, it should be in everyone's interest to interpret the existing data on medical topics objectively and neutrally, without rushing to premature, far-reaching conclusions which could confuse physicians and even render future therapy with potentially life-saving drugs impossible.
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